KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) (original) (raw)

References

  1. Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–280.
    Article CAS Google Scholar
  2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA, FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
    Article CAS Google Scholar
  3. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H . Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997; 90: 4271–4277.
    CAS PubMed Google Scholar
  4. Ross TS, Bernard OA, Berger R, Gilliland DG . Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998; 91: 4419–4426.
    CAS PubMed Google Scholar
  5. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000; 60: 3592–3598.
    CAS PubMed Google Scholar
  6. Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001; 97: 3910–3918.
    Article CAS Google Scholar
  7. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001; 98: 2518–2525.
    Article CAS Google Scholar
  8. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003; 102: 4187–4190.
    Article CAS Google Scholar
  9. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004; 64: 2673–2676.
    Article CAS Google Scholar
  10. Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 2004; 64: 2649–2651.
    Article CAS Google Scholar
  11. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG . The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996; 93: 14845–14850.
    Article CAS Google Scholar
  12. Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 1999; 93: 1707–1714.
    CAS Google Scholar
  13. Baxter EJ, Kulkarni S, Vizmanos JL, Jaju R, Martinelli G, Testoni N et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003; 120: 251–256.
    Article CAS Google Scholar
  14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
    Article CAS Google Scholar
  15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.
    Article CAS Google Scholar
  16. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487.
    Article CAS Google Scholar
  17. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE . Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 2002; 100: 1088–1091.
    Article CAS Google Scholar
  18. Dierlamm J, Wlodarska I, Michaux L, La Starza R, Zeller W, Mecucci C et al. Successful use of the same slide for consecutive fluorescence in situ hybridization experiments. Genes Chromosomes Cancer 1996; 16: 261–264.
    Article CAS Google Scholar
  19. Golub TR, Barker GF, Lovett M, Gilliland DG . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316.
    Article CAS Google Scholar
  20. Willis TG, Jadayel DM, Coignet LJ, Abdul-Rauf M, Treleaven JG, Catovsky D et al. Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood 1997; 90: 2456–2464.
    CAS Google Scholar
  21. Kikuno R, Nagase T, Nakayama M, Koga H, Okazaki N, Nakajima D et al. HUGE: a database for human KIAA proteins, a 2004 update integrating HUGEppi and ROUGE. Nucleic Acids Res 2004; 32, (Database issue: D502-4).
  22. Oshita A, Kishida S, Kobayashi H, Michiue T, Asahara T, Asashima M et al. Identification and characterization of a novel Dvl-binding protein that suppresses Wnt signalling pathway. Genes Cells 2003; 8: 1005–1017.
    Article CAS Google Scholar
  23. Kramer H, Phistry M . Genetic analysis of hook, a gene required for endocytic trafficking in drosophila. Genetics 1999; 151: 675–684.
    CAS PubMed PubMed Central Google Scholar
  24. Kramer H, Phistry M . Mutations in the Drosophila hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. J Cell Biol 1996; 133: 1205–1215.
    Article CAS Google Scholar
  25. Hosono S, Faruqi AF, Dean FB, Du Y, Sun Z, Wu X et al. Unbiased whole-genome amplification directly from clinical samples. Genome Res 2003; 13: 954–964.
    Article CAS Google Scholar

Download references